Myriad Genetics
MYGNAlgoritmens signaler
- ›Starkt 3m-momentum (+110.3%)
- ›Starkt 6m-momentum (+32.3%)
- ›Pris över MA50 och MA200 (uppåttrend)
- ›Hög volatilitet (84% årlig)
- ›+132% från 52v-botten
- ›Ökad handelsvolym (+73%)
📰 Senaste nyheter & analys
Källor: Placera, Nyhetsbyrån Direkt, Google NewsMyriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History - Yahoo! Finance Canada
2 d sedanMyriad Genetics, Inc. (MYGN) Stock Price, News, Quote & History Yahoo! Finance Canada
Yahoo! Finance CanadaMyriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN) - Seeking Alpha
2026-10-22Myriad Genetics: Prenatal Sale Provides A Lifeline In A Tough Spot (NASDAQ:MYGN) Seeking Alpha
Seeking AlphaMyriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions - Yahoo Finance
2026-10-22Myriad Genetics (MYGN) Stock Sees Fair Value Lift After Split Analyst Revisions Yahoo Finance
Yahoo FinanceMyriad Genetics (MYGN) Stock Forecast & Analyst Ratings - Moomoo
2026-10-21Myriad Genetics (MYGN) Stock Forecast & Analyst Ratings Moomoo
MoomooMyriad Genetics stock surges on $210M prenatal unit sale - Yahoo Finance
2026-10-20Myriad Genetics stock surges on $210M prenatal unit sale Yahoo Finance
Yahoo FinanceWhy Is Myriad Genetics (MYGN) Stock Soaring Today - Yahoo Finance
2026-10-02Why Is Myriad Genetics (MYGN) Stock Soaring Today Yahoo Finance
Yahoo FinanceWhy Myriad Genetics (MYGN) Stock Is Down Today - Yahoo Finance
2026-09-01Why Myriad Genetics (MYGN) Stock Is Down Today Yahoo Finance
Yahoo FinanceMyriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears - Webull
2026-08-01Myriad Genetics (MYGN) Stock Sinks As Revenue Reset Deepens Loss Fears Webull
WebullMyriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy
2025-09-23Myriad Genetics and SOPHiA GENETICS to Develop an Innovative Companion Diagnostic Offering in Liquid Biopsy PR Newswire SALT LAKE CITY and BOSTON, Sept. 23, 2025 SALT LAKE CITY and BOSTON , Sept
SOPHiA GENETICSPR NewswireSecurities Fraud Investigation Into Myriad Genetics, Inc. (MYGN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
2025-05-08Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASD
Myriad GeneticsBusiness WireMyriad Genetics, Inc. (MYGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
2025-05-08Law Offices of Howard G. Smith announces an investigation on behalf of Myriad Genetics, Inc. (“Myriad” or the “Company”) (NASDAQ: MYGN) investors concerning the Company’s possible violations of federa
Myriad GeneticsBusiness WireMYGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Myriad Genetics, Inc. and Encourages Investors to Contact the Firm
2024-11-14Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Myriad Genetics, Inc. (“Myriad” or “the Company”) (NASDAQ: MYGN). Investors who pu
Myriad GeneticsBusiness WireBREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD
2023-09-28BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD PR Newswire SALT LAKE CITY, Sept. 28, 2023 SALT LAKE CITY , Sept. 28, 2023 /PRNewswire/ -- A new
Myriad GeneticsPR NewswireIllumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
2023-03-02Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States PR Newswire SAN DIEGO, March 2, 2023 Strategic partnership offers a unique combination of diagn
IlluminaPR NewswireNew Study Published in Clinical Cancer Research Journal Highlights Use of EndoPredict Test to Inform Treatment for Premenopausal Breast Cancer Patients
2022-08-31Myriad Genetics’ EndoPredict test accurately identified premenopausal women with ER+, HER2- breast cancer who could safely avoid adjuvant chemotherapy SALT LAKE CITY, Aug. 31, 2022 (GLOBE NEWSWIRE) -
Myriad Genetics IncGlobeNewswireMyriad Genetics Partners with Institut für Hämopathologie Hamburg and Centre Georges-Francois LeClerc to Expand Access to Genetic Testing in Europe
2022-08-16Collaboration brings MyChoice CDx Plus Testing to Hamburg, Germany and Dijon, France Latest expansions represent Myriad’s commitment to growing international lab partner program SALT LAKE CITY, Aug.
Myriad Genetics IncGlobeNewswire
Klicket på "Köp i Nordnet" öppnar din Nordnet-app om installerad — där loggar du in med BankID. Annars öppnas Nordnets webbsajt där du kan logga in med BankID på samma sätt.